Cost-benefit of stockpiling drugs for influenza pandemic

Ran D. Balicer, Michael Huerta, Nadav Davidovitch, Itamar Grotto

Research output: Contribution to journalArticlepeer-review

76 Scopus citations

Abstract

We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts.

Original languageEnglish
Pages (from-to)1280-1282
Number of pages3
JournalEmerging Infectious Diseases
Volume11
Issue number8
DOIs
StatePublished - 1 Jan 2005

Fingerprint

Dive into the research topics of 'Cost-benefit of stockpiling drugs for influenza pandemic'. Together they form a unique fingerprint.

Cite this